Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality, pricey and fading Quality Strong, Valuation Expensive, Momentum Bearish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) headquartered in Hyderabad. Founded in 1984, the company produces active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs. Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #24 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 26 Mar 2026 | Davuluri Saharsh Rao | Promoter | Pledge | 0 | ₹116.12 Cr |
| 5 Mar 2026 | Deepthi Davuluri | Promoter group | Buy | 0 | ₹0 |
| 5 Mar 2026 | Davuluri Saharsh Rao | Promoter | Sell | 0 | ₹0 |
| 17 Dec 2025 | Ms. Kamala Tayaramma Kommula | Promoter group | Buy | 0 | ₹0 |
| 17 Dec 2025 | Mr. Gannabathula Venkata Krishna Rama Rao | Promoter | Sell | 0 | ₹0 |
| 24 Sep 2025 | Mr. Gannabathula Venkata Krishna Rama Rao | Promoter | Sell | 0 | ₹0 |
| 24 Sep 2025 | Mr.Gannabathula Veeravenkata Satyanarayanamurty | Promoter group | Buy | 0 | ₹0 |
| 24 Sep 2025 | Ms. Gannabathula Venkata Vani Sriranganayakamma | Promoter group | Buy | 0 | ₹0 |
| 1 Mar 2025 | Davuluri Ownership Trust | Promoter | Buy | 0 | ₹0 |
| 1 Mar 2025 | Saharsh Rao Davuluri | Promoter | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 6 Aug 2026 | HDFC MUTUAL FUND | Bulk | Buy | 64,547 | 21585.0000 | NSE |
| 5 Sep 2025 | AIRAVAT CAPITAL TRUST II | Block | Buy | 8,896 | 14612.0000 | NSE |
| 5 Sep 2025 | AIRAVAT CAPITAL TRUST | Block | Sell | 8,896 | 14612.0000 | NSE |
| 26 Jun 2024 | SMALLCAP WORLD FUND INC | Block | Buy | 130,000 | 7400.0000 | BSE |
| 26 Jun 2024 | MALABAR INDIA FUND LIMITED | Block | Sell | 130,000 | 7400.0000 | BSE |
| 26 Jun 2024 | SMALLCAP WORLD FUND INC | Bulk | Buy | 130,000 | 7400.0000 | BSE |
| 26 Jun 2024 | MALABAR INDIA FUND LIMITED | Bulk | Sell | 130,000 | 7400.0000 | BSE |
| 8 Dec 2023 | RAMAMOHAN RAO DAVULURI | Bulk | Sell | 400,000 | 5012.4500 | BSE |
| 31 Aug 2023 | BNP PARIBAS ARBITRAGE | Bulk | Sell | 64,893 | 3871.3100 | NSE |
| 15 May 2023 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Buy | 73,921 | 2858.7600 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 24 Jul 2026 | Dividend - Rs 34 Per Share | 34.0000 | 24 Jul 2026 |
| 18 Jul 2025 | Dividend - Rs 12 Per Share | 12.0000 | 18 Jul 2025 |
| 12 Jul 2024 | Annual General Meeting/Dividend - Rs 14 Per Share | 14.0000 | — |
| 11 Jul 2023 | Annual General Meeting/Dividend - Rs 10 Per Share | 10.0000 | — |
| 14 Jul 2022 | Annual General Meeting/Dividend - Rs 5 Per Share | 5.0000 | 15 Jul 2022 |
| 29 Jun 2021 | Annual General Meeting/Dividend - Rs 3 Per Share | 3.0000 | — |
| 10 Nov 2020 | Interim Dividend - Rs 2 Per Share | 2.0000 | 11 Nov 2020 |
| 18 Feb 2020 | Interim Dividend - Rs 2 Per Share | 2.0000 | 20 Feb 2020 |
| 27 Jun 2019 | Annual General Meeting/Dividend - Rs 1.20 Per Share | 1.2000 | — |
| 4 Aug 2016 | Annual General Meeting/ Dividend - Rs 2/- Per Share | 2.0000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 2 Jul 2020 | OTHER | Annual General Meeting |
| 3 Aug 2018 | OTHER | Annual General Meeting |
| 21 Dec 2017 | OTHER | Annual General Meeting (Date Revised) |
| 13 Aug 2014 | RIGHTS | Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share |
| 3 Aug 2012 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 5 Aug 2026 | Financial Results | Yes |
| 12 May 2026 | Financial Results/Dividend | Yes |
| 9 Feb 2026 | Financial Results | Yes |
| 7 Nov 2025 | Financial Results | Yes |
| 31 Jul 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 25 Sep 2026 | Trading Window | Neuland Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 25 Sep 2026 | Insider Trading / SAST | Neuland Laboratories Ltd - 524558 - Closure of Trading Window |
| 16 Sep 2026 | Company Update | Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 16 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026 |
| 15 Sep 2026 | Company Update | Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 15 Sep 2026 | Press Release | Neuland Laboratories Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Press Release". |
| 9 Sep 2026 | Company Update | Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 9 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026 |
| 7 Sep 2026 | Updates | Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'. |
| 25 Aug 2026 | Credit Rating | Neuland Laboratories Limited has informed the Exchange about Credit Rating |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
